Affymax Inc (NASDAQ:AFFY) up by 5.51%, Columbia Laboratories Inc (NASDAQ:CBRX)

Posted by Samantha Donahue May 21, 2013 0 Comment 3291 views


Affymax, Inc (NASDAQ:AFFY): In Tuesday’s trading session, Affymax, Inc (NASDAQ:AFFY) jumped 5.51%. Its opening price of $1.34 rose to touch an intraday high of $1.36 which eventually headed down to currently trade at $1.34 per share. Over 1.86 million shares exchanged hands in the current trading session. This number stood below the average volume of 7.17 million that was measured over a 30-day period.

Affymax, Inc (NASDAQ:AFFY) is a bio-pharma company. It is involved in the development of drugs that are used in the treatment of different serious and life-threatening conditions. Peginesatide, which is its product candidate, is used for the treatment of anemia in dialysis patients who suffer from chronic kidney disease.  It is essentially a synthetic peptide-based erythropoiesis stimulating agent that is designed to stimulate the production of red blood cells. AFFY has a global collaboration for the development and commercialization of peginesatide, with Takeda, the pharma company. As of 31 December 2011, in excess of 2,600 patients have received peginesatide in various different clinical trials. As of 2011 Dec, its NDA or New Drug Application for peginesatide was being reviewed by the U.S, Food and Drug Administration (FDA).

Columbia Laboratories Inc (NASDAQ:CBRX): In Tuesday’s trading session, Columbia Laboratories Inc (NASDAQ:CBRX) traded flat Its opening price of $0.63 rose to touch an intraday high of $0.65 which eventually headed down to currently trade at $0.62 per share. Over 0.139 million shares exchanged hands in the current trading session. This number stood below the average volume of 0.342 million that was measured over a 30-day period.

CBRX is involved in the development, manufacture and sale of pharmaceutical products. These products use its bio-adhesive drug delivery technologies and are used in the treatment of various medical conditions. As of 31 December 2011, Columbia Laboratories Inc (NASDAQ:CBRX) developed and marketed five bio-adhesive vaginal gel products. These provide solutions for pregnancy support, infertility, amenorrhea as well as other gynecological conditions. All the products that have been developed by the company, utilize its BDS delivery system (BDS). This primarily consists of a polymer (polycarbophil) as well as an active ingredient. CBRX’s Progesterone products include PROCHIEVE and CRINONE. Its PROCHIEVE and CRINONE vaginal gel products are manufactured in bulk by a company called Fleet Laboratories Limited in the U.K.


About Samantha Donahue

Samantha Donahue is a digital fellow with GDP insider. Samantha earned a Bachelor's degree in Government from Cornell University and later his Master's degree in Journalism from Columbia University. She has also received numerous awards from the Associated Press, Society of Professional Journalists, and other media organizations for many of her exclusive stories. Samantha thrives reporting on breaking news and as a general assignments news reporter.

View all post by Samantha Donahue Visit author's website

Write Your Comment